DK3518948T5 - Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira - Google Patents
Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira Download PDFInfo
- Publication number
- DK3518948T5 DK3518948T5 DK17857734.2T DK17857734T DK3518948T5 DK 3518948 T5 DK3518948 T5 DK 3518948T5 DK 17857734 T DK17857734 T DK 17857734T DK 3518948 T5 DK3518948 T5 DK 3518948T5
- Authority
- DK
- Denmark
- Prior art keywords
- oncolytic
- enhancing
- spread
- growth
- compositions
- Prior art date
Links
- 230000000174 oncolytic effect Effects 0.000 title 2
- 241000700605 Viruses Species 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20271—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662403586P | 2016-10-03 | 2016-10-03 | |
PCT/CA2017/051176 WO2018064762A1 (en) | 2016-10-03 | 2017-10-03 | Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses |
Publications (2)
Publication Number | Publication Date |
---|---|
DK3518948T3 DK3518948T3 (da) | 2023-07-24 |
DK3518948T5 true DK3518948T5 (da) | 2024-09-02 |
Family
ID=61830768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17857734.2T DK3518948T5 (da) | 2016-10-03 | 2017-10-03 | Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira |
Country Status (11)
Country | Link |
---|---|
US (1) | US11517598B2 (da) |
EP (1) | EP3518948B1 (da) |
CN (1) | CN110022889B (da) |
CA (1) | CA3034983A1 (da) |
DK (1) | DK3518948T5 (da) |
ES (1) | ES2950435T3 (da) |
FI (1) | FI3518948T3 (da) |
HR (1) | HRP20230698T1 (da) |
PT (1) | PT3518948T (da) |
SI (1) | SI3518948T1 (da) |
WO (1) | WO2018064762A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3116192A1 (en) * | 2018-11-06 | 2020-05-14 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
MX2021005667A (es) * | 2018-11-14 | 2021-10-13 | Broad Inst Inc | Composiciones de vanadio y métodos para el tratamiento del cáncer. |
CN113876957A (zh) * | 2020-07-01 | 2022-01-04 | 青岛海洋生物医药研究院股份有限公司 | Stat2磷酸化水平调节剂的用途 |
US20240293352A1 (en) * | 2021-05-07 | 2024-09-05 | Ottawa Hospital Research Institute | Pharmaceutical compositions comprising vanadium salts |
CN114427010A (zh) * | 2021-12-28 | 2022-05-03 | 云舟生物科技(广州)股份有限公司 | 一种检测水疱性口炎病毒滴度的引物、试剂盒及方法 |
WO2023225268A1 (en) * | 2022-05-19 | 2023-11-23 | The University Of Chicago | Vanadyl sulfate compositions and methods of use therefor for the treatment and prevention of aging-related diseases and cancer |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9814036D0 (en) * | 1998-06-29 | 1998-08-26 | Univ Dundee | Materials and methods relating to the induction of apoptosis in target cells |
IL145899A0 (en) | 1999-04-15 | 2002-07-25 | Pro Virus Inc | Treatment of neoplasms with viruses |
US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
EP2177619A1 (en) | 2000-01-21 | 2010-04-21 | BioVex Limited | HSV strains for the oncolytic treatment of cancer |
AU2001279264B2 (en) | 2000-06-26 | 2005-04-28 | University Of Ottawa | Purging of cells using viruses |
DE60142485D1 (de) | 2000-11-09 | 2010-08-12 | Oncolytics Biotech Inc | Verfahren zur Beurteilung von zellulären proliferativen Erkrankungen |
EP1385466B1 (en) | 2001-05-11 | 2011-03-09 | Wellstat Biologics Corporation | Oncolytic virus therapy |
US20040115170A1 (en) | 2001-11-30 | 2004-06-17 | Brown Earl Garnet | Oncolytic virus |
CN101161248B (zh) * | 2007-11-06 | 2011-05-04 | 辽宁大学 | 一种抗乙型肝炎病毒药物的制备方法 |
CU20080028A6 (es) * | 2008-02-29 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus |
PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
EP2661278B1 (en) * | 2011-01-04 | 2019-06-19 | SillaJen Biotherapeutics, Inc. | Tumor specific complement dependent cytotoxicity (cdc) antibodies generated by administration of oncolytic vaccinia virus, for use in the treatment of cancer |
BR112020009907A2 (pt) * | 2017-11-24 | 2020-11-03 | Ottawa Hospital Research Institute | composições e métodos para melhorar produção, crescimento, disseminação, ou eficácia oncolítica e imunoterapêutica de vírus sensíveis a interferon |
-
2017
- 2017-10-03 DK DK17857734.2T patent/DK3518948T5/da active
- 2017-10-03 FI FIEP17857734.2T patent/FI3518948T3/fi active
- 2017-10-03 SI SI201731381T patent/SI3518948T1/sl unknown
- 2017-10-03 PT PT178577342T patent/PT3518948T/pt unknown
- 2017-10-03 EP EP17857734.2A patent/EP3518948B1/en active Active
- 2017-10-03 CN CN201780073469.XA patent/CN110022889B/zh active Active
- 2017-10-03 US US16/339,294 patent/US11517598B2/en active Active
- 2017-10-03 ES ES17857734T patent/ES2950435T3/es active Active
- 2017-10-03 WO PCT/CA2017/051176 patent/WO2018064762A1/en unknown
- 2017-10-03 CA CA3034983A patent/CA3034983A1/en active Pending
- 2017-10-03 HR HRP20230698TT patent/HRP20230698T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PT3518948T (pt) | 2023-07-17 |
CN110022889A (zh) | 2019-07-16 |
US20190231832A1 (en) | 2019-08-01 |
WO2018064762A1 (en) | 2018-04-12 |
US11517598B2 (en) | 2022-12-06 |
DK3518948T3 (da) | 2023-07-24 |
EP3518948A4 (en) | 2020-06-24 |
SI3518948T1 (sl) | 2023-09-29 |
EP3518948A1 (en) | 2019-08-07 |
EP3518948B1 (en) | 2023-04-12 |
CN110022889B (zh) | 2024-05-10 |
CA3034983A1 (en) | 2018-04-12 |
HRP20230698T1 (hr) | 2023-10-13 |
FI3518948T3 (fi) | 2023-07-18 |
ES2950435T3 (es) | 2023-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3510157T3 (da) | Pd-1-homing-endonucleasevarianter, sammensætninger og fremgangsmåder til anvendelse | |
DK3386534T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
DK3676297T3 (da) | Forbindelser, sammensætninger og fremgangsmåder | |
DK3407888T3 (da) | Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser | |
DK3842442T3 (da) | Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet | |
DK3580561T3 (da) | Hla-baserede metoder, sammensætninger og anvendelse heraf | |
DK3518948T3 (da) | Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira | |
DK4104687T3 (da) | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe | |
DK3012322T3 (da) | Gendeleteret stamme af porcint pseudorabiesvirus, vaccinesammensætning og fremgangsmåde til fremstilling deraf og anvendelse deraf | |
DK3368541T3 (da) | Sammensætninger og metoder til inhibiering af arginaseaktivitet | |
DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
DK3307872T3 (da) | Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober | |
DK3390430T3 (da) | Human immundefektvirus-antigener, vektorer, sammensætninger og fremgangsmåder til anvendelse deraf | |
DK3325669T3 (da) | Sammensætninger og fremgangsmåder til RNA-analyse | |
DK3302709T3 (da) | Fremgangsmåder og sammensætninger til rna-guidet behandling af hiv-infektion | |
DK3262008T3 (da) | Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed | |
DK3604294T3 (da) | Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter | |
DK3506886T3 (da) | Højkoncentrerede lavviskositets-masp-2-inhiberende antistofformuleringer, kits og fremgangsmåder | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
DK3172233T3 (da) | Anti-cd74-antistoffer, sammensætninger omfattende anti-cd74- antistoffer og fremgangsmåder til anvendelse af anti-cd74-antistoffer | |
DK3305310T3 (da) | Onkolytisk virusformulering og fremgangsmåde til fremstilling deraf | |
DK3394272T5 (da) | Sammensætninger og fremgangsmåder til effektiv målretning af transgener |